Very rapid virologic response and early HCV response kinetics, as quick measures to compare efficacy and guide a personalized response-guided therapy.
BACKGROUND
This is the second and final report for our study designed to compare two generic sofosbuvir products for the degree and speed of virologic response to a dual anti-hepatitis C virus (HCV) treatment protocol. We aimed to test the applicability of the early virus response kinetics and the very rapid virologic response (vRVR) rate as quick outcome measures for accelerated comparative efficacy studies and as a foundation for a personalized response-guided therapy.


METHODS
Fifty eligible chronic HCV patients were randomized to either one of two generic sofosbuvir products (Gratisovir or Grateziano) at a daily dose of one 400 mg tablet plus a weight-based ribavirin dose. Data were compared between the groups for early virus response kinetics and vRVR rates in relation to the rates of final sustained virologic response at week 12 posttreatment (SVR12).


RESULTS
The Log10 transformed virus load (Log polymerase chain reaction) curves showed fairly similar rapid decline during the first 2 weeks, with no significant difference between the groups at four analysis points throughout the study by repeated-measures factorial analysis of variance test (P=0.48). The SVR12 rates were 96% (95% confidence interval, 79.6%-99.9%) in Gratisovir group (24/25) and 95.7% (95% confidence interval, 78%-99.9%) in Grateziano group (22/23). There was no statistically significant difference found by exact test (P>0.999). There was a significant association between the vRVR and the SVR12, with 100% positive predictive value (38/38 of those who had vRVR, achieved a final SVR12) and 82.6% sensitivity (among the total 46 with SVR12, 38 were having vRVR).


CONCLUSIONS
We can conclude from our study that the early HCV response kinetics and the vRVR rates could be used as sensitive quick markers for efficacy (with a very high positive predictive value for SVR12), based on our accelerated comparative efficacy research model. This might open the way for new models of accelerated equivalence efficacy studies along with the bioequivalence kinetics studies to test a generic drug against a reference. Also, the early response kinetics and the vRVR might be used as qualifiers for a personalized course of treatment. This could shorten unnecessarily long treatment courses in rapid responders and might help to avoid relapses in slow responders.
Green Clinical Research Center; Abbas Helmy Clinics.
Mostafa
M
Yakoot
Tropical Medicine and Hepatology Department, Alexandria Faculty of Medicine.
Alaa M
AM
Abdo
Microbiology Department, High Institute of Public Health, Alexandria University; Mabarat Asafra Labs.
Ahmed
A
Yousry
Pharco Corporation, Alexandria, Egypt.
Sherine
S
Helmy
D000998:Antiviral Agents / Q000008:administration & dosage / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D005260:Female; D016174:Hepacivirus / Q000187:drug effects*; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000821:virology*; D006801:Humans; D007700:Kinetics; D008297:Male; D008875:Middle Aged; D057285:Precision Medicine; D012254:Ribavirin / Q000008:administration & dosage / Q000494:pharmacology*; D013329:Structure-Activity Relationship; D013607:Tablets; D019562:Viral Load / Q000187:drug effects
D000998:Antiviral Agents; D013607:Tablets; D012254:Ribavirin
HCV response kinetics; chronic hepatitis C; direct-acting antiviral agents; dual therapy; ribavirin; sofosbuvir; vRVR; very rapid virologic response